Company / Capital Returned to Shareholders
Abbott Laboratories Capital Returned to Shareholders History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Returned to Shareholders
$5.0B
FY2025
5-year range
$3.0B / $5.5B
FY2021-FY2025
Trend
-2.4%
vs FY2024
Sector context
#4 of 108
Health Care
What the data says
Among 108 Health Care companies, Abbott Laboratories is in the top 4% for capital returned to shareholders. Capital Returned to Shareholders has fluctuated over the past 10 years, ranging from $2.1B in FY2018 to $5.5B in FY2023.
Based on SEC 10-K filings.
$5.0B in FY2025 with a 5-year CAGR of +17.8%. Top quartile in the Health Care sector.
Declined from $5.5B to $5.0B over the past 2 years.
Health Care sector context is included.
Capital Returned to Shareholders over time
Growth rates
- 3-Year CAGR
- +19.1%
- 5-Year CAGR
- +17.8%
- 10-Year CAGR
- -
Sector benchmark
+572.9% above sector average
Key checks
Key Insights
- 5-year CAGR of +17.8%, indicating consistent growth.
- In FY2025, capital returned to shareholders decreased 2.4% year-over-year.
- Ranks #4 out of 108 companies in the Health Care sector.
- Peak capital returned to shareholders was recorded in FY2023.
Company context
Key Data Points
- Strong profit margin: 31.9%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 27.4%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital Returned to ShareholdersValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $5.0B | -2.4% |
| FY2024 | $5.1B | -6.7% |
| FY2023 | $5.5B | +85.7% |
| FY2022 | $3.0B | -0.8% |
| FY2021 | $3.0B | +35.1% |
| FY2020 | $2.2B | -26.0% |
| FY2019 | $3.0B | +45.0% |
| FY2018 | $2.1B | -44.0% |
| FY2017 | $3.7B | +4.0% |
| FY2016 | $3.5B | +42.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026